Continuous Glucose Monitoring (CGM) in Type 1 Diabetes
Introduction And Pathophysiological Rationale
- India bears a massive pediatric Type 1 Diabetes (T1D) burden, with 100,000 to 150,000 affected children and a 6.7% annual incidence rise.
- Traditional self-monitoring of blood glucose (SMBG) is burdensome, frequently misses nocturnal or asymptomatic hypoglycemia, and fails to capture the glycemic variability responsible for long-term complications.
- Continuous Glucose Monitoring (CGM) systems utilize real-time (rtCGM) and intermittently scanned (isCGM) technology to provide 288 or more daily interstitial glucose readings, predictive alarms, and trend data.
- Modern 2026 devices (e.g., Dexcom G7, FreeStyle Libre 3) feature factory calibration, smartphone integration, and extended 10 to 14-day wear times.
Clinical Benefits And Evidence (2024β2026)
- Early initiation at diagnosis successfully prevents diabetic ketoacidosis (DKA) and enhances long-term neurocognitive and physical growth outcomes.
- Multicenter registries report CGM adoption rising from 18.7% to 81.7%, directly correlating with reduced severe hypoglycemia and improved HbA1c.
- Integration with automated insulin delivery (AID) systems achieves a 0.4 to 1.0% HbA1c reduction without elevating hypoglycemia risk.
- Minimizes parental stress, improves sleep quality, and supports school and exercise integration.
Standardized CGM Metrics And Targets
- Modern guidelines prioritize CGM metrics over isolated HbA1c values for predicting complication risks.
| Metric | Definition | Target Goal |
|---|---|---|
| Time In Range (TIR) | Glucose between 70 and 180 mg/dL | > 70% |
| Time Below Range (TBR) | Glucose < 70 mg/dL | < 4% |
| Severe TBR | Glucose < 54 mg/dL | < 1% |
| Time Above Range (TAR) | Glucose > 180 mg/dL | < 25% |
Current Society Guidelines
International Consensus
- ISPAD 2024 (Published 2025): Strongly recommends factory-calibrated CGM as the standard of care for all children and adolescents. Lowers the optimal HbA1c target to β€6.5% when utilizing CGM or AID technology.
- ADA 2026: Recommends offering CGM immediately at diagnosis (Level A evidence) and mandates robust school support policies for CGM users.
Indian Guidelines And MoHFW Integration
- IAP 2025β2026: Endorses ISPAD and ADA recommendations, prioritizing integration with the Rashtriya Bal Swasthya Karyakram (RBSK).
- MoHFW (May 2026): Issued the landmark Guidance Document on Diabetes Mellitus in Children, mandating universal screening via the 4Ts (Toilet, Thirsty, Tired, Thinner).
- CGM is acknowledged in tertiary care pathways and selectively covered under Ayushman Bharat (PM-JAY) empaneled centers.
Implementation Challenges And Future Horizons
- Indian implementation is severely hindered by high device costs (2,000 to 5,000 rupees monthly), limited rural access, and the digital divide.
- Ongoing trials focus on dual continuous ketone-glucose sensors for preemptive DKA prevention and AI-driven predictive algorithms.